Department of General Surgery, Koç University School of Medicine, Istanbul, Turkey.
Department of General Surgery, VKV American Hospital, Istanbul, Turkey.
Int J Colorectal Dis. 2023 Sep 14;38(1):229. doi: 10.1007/s00384-023-04526-2.
This study aimed to compare local regrowth rates after total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (SNCRT) in locally advanced rectal cancer (LARC) patients that were strictly selected and assessed with a multimodal approach. Secondary outcomes were 4-year disease-free (DFS) and overall survival (OS) rates.
Locally advanced rectal cancer patients without distant metastases treated at Koç Healthcare Group between January 2014 and January 2021 were included. Patients were assessed for complete response with a combination of digital rectal exam, endoscopy, and magnetic resonance imaging with a dedicated rectum protocol. The systemic evaluation was performed with an upper abdomen MRI using intravenous hepatobiliary contrast agent and a thorax CT.
Of the 270 patients with LARC, 182 fulfilled the inclusion criteria. Ninety-seven (53.3%) underwent TNT, while 85 (46.7%) underwent SNCRT. A cumulative combination of pathological and sustained clinical complete response was significantly higher in the TNT group than in the SNCRT (45.4% vs. 20.0%, p < 0.0001). After a median follow-up of 48 months, seven patients in the W&W group had regrowth [TNT: 4 (10.8%) vs. SNCRT: 3 (23.1%), p = 0.357]. Based on pathological examination, complete/near complete mesorectum rates (p = 1.000) and circumferential resection margin positivity rates (p = 1.000) were similar between the groups. The 4-year DFS and OS rates were comparable. The patients with clinical or pathological complete response had significantly longer overall survival (p = 0.017) regardless of the type of neoadjuvant treatment.
Multimodal assessment after TNT effectively detects complete responders, resulting in low local recurrence and increased cumulative complete response rates. However, these outcomes did not translate into a survival advantage.
本研究旨在比较严格选择并采用多模态方法评估的局部进展期直肠癌(LARC)患者在接受全新辅助治疗(TNT)与标准新辅助放化疗(SNCRT)后的局部复发率。次要结局为 4 年无病(DFS)和总生存(OS)率。
纳入 2014 年 1 月至 2021 年 1 月期间在科奇医疗集团接受治疗的无远处转移的局部进展期直肠癌患者。通过数字直肠检查、内镜和磁共振成像(专用直肠协议)相结合评估患者的完全缓解情况。采用静脉肝胆对比剂的上腹部 MRI 和胸部 CT 进行系统评估。
在 270 例 LARC 患者中,有 182 例符合纳入标准。97 例(53.3%)接受了 TNT,85 例(46.7%)接受了 SNCRT。TNT 组的病理和持续临床完全缓解的累积组合率显著高于 SNCRT 组(45.4%比 20.0%,p<0.0001)。中位随访 48 个月后,W&W 组中有 7 例患者出现肿瘤复发[TNT:4 例(10.8%)比 SNCRT:3 例(23.1%),p=0.357]。基于病理检查,完全/接近完全直肠系膜切除率(p=1.000)和环周切缘阳性率(p=1.000)在两组间相似。两组的 4 年 DFS 和 OS 率相当。无论新辅助治疗类型如何,具有临床或病理完全缓解的患者的总生存时间显著延长(p=0.017)。
TNT 后的多模态评估可有效检测完全缓解者,从而降低局部复发率并提高累积完全缓解率。然而,这些结果并未转化为生存优势。